NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Given Average Rating of “Hold” by Analysts

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has received a consensus recommendation of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $11.6667.

NMTC has been the subject of several research reports. LADENBURG THALM/SH SH boosted their price target on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Weiss Ratings cut shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th.

Insider Activity at NeuroOne Medical Technologies

In other news, Director Mark Christianson sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total value of $31,800.00. Following the transaction, the director directly owned 20,692 shares of the company’s stock, valued at approximately $65,800.56. This trade represents a 32.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 11.80% of the stock is owned by company insiders.

Institutional Trading of NeuroOne Medical Technologies

Hedge funds have recently bought and sold shares of the business. Legato Capital Management LLC purchased a new stake in shares of NeuroOne Medical Technologies in the fourth quarter valued at approximately $34,000. Squarepoint Ops LLC purchased a new position in NeuroOne Medical Technologies during the fourth quarter worth approximately $36,000. Susquehanna International Group LLP purchased a new position in NeuroOne Medical Technologies during the third quarter worth approximately $47,000. XTX Topco Ltd acquired a new position in NeuroOne Medical Technologies during the second quarter worth $51,000. Finally, Goldman Sachs Group Inc. acquired a new position in NeuroOne Medical Technologies during the first quarter worth $84,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

NeuroOne Medical Technologies Price Performance

NeuroOne Medical Technologies stock traded up $0.13 during midday trading on Friday, reaching $2.88. The company had a trading volume of 438,595 shares, compared to its average volume of 26,452. NeuroOne Medical Technologies has a 12-month low of $2.57 and a 12-month high of $6.96. The company has a market capitalization of $25.06 million, a P/E ratio of -3.39 and a beta of 0.54. The firm’s fifty day simple moving average is $3.62 and its 200-day simple moving average is $4.34.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The firm had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $2.58 million. NeuroOne Medical Technologies had a negative return on equity of 99.43% and a negative net margin of 68.35%. On average, analysts expect that NeuroOne Medical Technologies will post -0.36 EPS for the current fiscal year.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.